Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Sanofi price target raised to EUR 100 from EUR 93 at JPMorgan » 14:38
07/30/21
07/30
14:38
07/30/21
14:38
SNY

Sanofi

$51.55 /

+0.03 (+0.06%)

JPMorgan analyst Richard…

JPMorgan analyst Richard Vosser raised the firm's price target on Sanofi to EUR 100 from EUR 93 and keeps an Overweight rating on the shares.

ShowHide Related Items >><<
SNY Sanofi
$51.55 /

+0.03 (+0.06%)

SNY Sanofi
$51.55 /

+0.03 (+0.06%)

07/29/21 H.C. Wainwright
Regeneron price target raised to $729 from $703 at H.C. Wainwright
07/26/21 Roth Capital
Translate Bio price target raised to $45 from $28 at Roth Capital
05/25/21 JPMorgan
Olema selloff brings 'compelling' entry point, says JPMorgan
04/30/21 Deutsche Bank
Sanofi price target raised to EUR 75 from EUR 70 at Deutsche Bank
SNY Sanofi
$51.55 /

+0.03 (+0.06%)

SNY Sanofi
$51.55 /

+0.03 (+0.06%)

SNY Sanofi
$51.55 /

+0.03 (+0.06%)

Yesterday
Recommendations
Regeneron price target raised to $729 from $703 at H.C. Wainwright » 12:58
07/29/21
07/29
12:58
07/29/21
12:58
REGN

Regeneron

$585.00 /

-1.51 (-0.26%)

, SNY

Sanofi

$51.32 /

-0.74 (-1.42%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Michael King raised the firm's price target on Regeneron Pharmaceuticals (REGN) to $729 from $703 and keeps a Buy rating on the shares after the company and Sanofi (SNY) announced Dupixent met all key primary and secondary endpoints in the Phase 3 trial for chronic spontaneous urticaria. The data continues to support Dupixent's "well-established" safety profile, King tells investors in a research note. The analyst updated his model to reflect the increased probability of success for Dupixent.

ShowHide Related Items >><<
SNY Sanofi
$51.32 /

-0.74 (-1.42%)

REGN Regeneron
$585.00 /

-1.51 (-0.26%)

REGN Regeneron
$585.00 /

-1.51 (-0.26%)

07/23/21 RBC Capital
Regeneron price target raised to $679 from $629 at RBC Capital
07/09/21 Jefferies
Aslan Pharmaceuticals initiated with a Buy at Jefferies
07/08/21 Benchmark
Regeneron price target raised to $636 from $590 at Benchmark
07/07/21 H.C. Wainwright
Silverback strikes pact with Regeneron for Libtayo, says H.C. Wainwright
SNY Sanofi
$51.32 /

-0.74 (-1.42%)

07/26/21 Roth Capital
Translate Bio price target raised to $45 from $28 at Roth Capital
05/25/21 JPMorgan
Olema selloff brings 'compelling' entry point, says JPMorgan
04/30/21 Deutsche Bank
Sanofi price target raised to EUR 75 from EUR 70 at Deutsche Bank
04/29/21 Barclays
Sanofi price target raised to EUR 90 from EUR 85 at Barclays
SNY Sanofi
$51.32 /

-0.74 (-1.42%)

REGN Regeneron
$585.00 /

-1.51 (-0.26%)

SNY Sanofi
$51.32 /

-0.74 (-1.42%)

REGN Regeneron
$585.00 /

-1.51 (-0.26%)

SNY Sanofi
$51.32 /

-0.74 (-1.42%)

REGN Regeneron
$585.00 /

-1.51 (-0.26%)

REGN Regeneron
$585.00 /

-1.51 (-0.26%)

Hot Stocks
Sanofi now sees FY21 business EPS up around 12% at CER » 06:35
07/29/21
07/29
06:35
07/29/21
06:35
SNY

Sanofi

$52.06 /

+0.505 (+0.98%)

Sanofi now expects 2021…

Sanofi now expects 2021 business EPS to grow around 12% at CER, barring unforeseen major adverse events. Applying average July 2021 exchange rates, the currency impact on 2021 business EPS is estimated to be between -4% to -5%.

ShowHide Related Items >><<
SNY Sanofi
$52.06 /

+0.505 (+0.98%)

SNY Sanofi
$52.06 /

+0.505 (+0.98%)

07/26/21 Roth Capital
Translate Bio price target raised to $45 from $28 at Roth Capital
05/25/21 JPMorgan
Olema selloff brings 'compelling' entry point, says JPMorgan
04/30/21 Deutsche Bank
Sanofi price target raised to EUR 75 from EUR 70 at Deutsche Bank
04/29/21 Barclays
Sanofi price target raised to EUR 90 from EUR 85 at Barclays
SNY Sanofi
$52.06 /

+0.505 (+0.98%)

SNY Sanofi
$52.06 /

+0.505 (+0.98%)

SNY Sanofi
$52.06 /

+0.505 (+0.98%)

Earnings
Sanofi reports Q2 business EPS EUR1.38, up 16.4% at CER » 06:35
07/29/21
07/29
06:35
07/29/21
06:35
SNY

Sanofi

$52.06 /

+0.505 (+0.98%)

Q2 sales grew double…

Q2 sales grew double digit to EUR 8.7 billion, up 12.4% at CER, mainly driven by Dupixent and Vaccines. CEO Paul Hudson commented: "The Sanofi business momentum has accelerated in the second quarter, delivering strong financial results driven by our core growth drivers Dupixent and Vaccines. We continue to deliver on our Play to Win strategy, and our second quarter performance gives us confidence in Sanofi's growth trajectory for this year. Consequently, we are raising our full-year EPS guidance to around 12%. Significant progress was made across several clinical and regulatory milestones and in June, we formed the Sanofi mRNA vaccines Center of Excellence with the aim to lead the field in this next chapter of vaccine innovation. We are well on our way making Sanofi more representative of communities we serve, executing on our Diversity and Inclusion strategy and creating a work environment where our people can bring their best selves to transform the practice of medicine."

ShowHide Related Items >><<
SNY Sanofi
$52.06 /

+0.505 (+0.98%)

SNY Sanofi
$52.06 /

+0.505 (+0.98%)

07/26/21 Roth Capital
Translate Bio price target raised to $45 from $28 at Roth Capital
05/25/21 JPMorgan
Olema selloff brings 'compelling' entry point, says JPMorgan
04/30/21 Deutsche Bank
Sanofi price target raised to EUR 75 from EUR 70 at Deutsche Bank
04/29/21 Barclays
Sanofi price target raised to EUR 90 from EUR 85 at Barclays
SNY Sanofi
$52.06 /

+0.505 (+0.98%)

SNY Sanofi
$52.06 /

+0.505 (+0.98%)

SNY Sanofi
$52.06 /

+0.505 (+0.98%)

Hot Stocks
Regeneron, Sanofi announce Dupixent trial met primary and secondary endpoints » 05:53
07/29/21
07/29
05:53
07/29/21
05:53
REGN

Regeneron

$586.33 /

+5.33 (+0.92%)

, SNY

Sanofi

$52.06 /

+0.505 (+0.98%)

Regeneron (REGN) and…

Regeneron (REGN) and Sanofi (SNY) announced a pivotal Phase 3 trial evaluating Dupixent in patients with moderate-to-severe chronic spontaneous urticaria, or CSU, met its primary and all key secondary endpoints at 24 weeks. Adding Dupixent to standard-of-care antihistamines significantly reduced itch and hives for biologic-naive patients, compared to antihistamines alone in Study A, the first of two trials of the LIBERTY-CUPID clinical program. In the trial, adding Dupixent to standard-of-care antihistamines nearly doubled the reduction in itch and urticaria activity compared to standard-of-care alone (placebo) with continuous improvement out to 24 weeks. Patients experienced a 63% reduction in itch severity with Dupixent versus 35% with placebo, as measured by a 0-21 point itch severity scale, the primary endpoint in the U.S.; 65% reduction in urticaria activity severity with Dupixent versus 37% with placebo, as measured by a 0-42 point urticaria activity scale, the secondary endpoint in the U.S. The trial demonstrated safety results similar to the known safety profile of Dupixent in its approved indications. For the 24-week treatment period, the occurrence of treatment emergent adverse events were generally similar between the Dupixent and placebo groups. The most common adverse events were injection site reactions. The potential use of Dupixent in CSU and EoE is currently under clinical development, and the safety and efficacy have not been fully evaluated by any regulatory authority.

ShowHide Related Items >><<
SNY Sanofi
$52.06 /

+0.505 (+0.98%)

REGN Regeneron
$586.33 /

+5.33 (+0.92%)

REGN Regeneron
$586.33 /

+5.33 (+0.92%)

07/23/21 RBC Capital
Regeneron price target raised to $679 from $629 at RBC Capital
07/09/21 Jefferies
Aslan Pharmaceuticals initiated with a Buy at Jefferies
07/08/21 Benchmark
Regeneron price target raised to $636 from $590 at Benchmark
07/07/21 H.C. Wainwright
Silverback strikes pact with Regeneron for Libtayo, says H.C. Wainwright
SNY Sanofi
$52.06 /

+0.505 (+0.98%)

07/26/21 Roth Capital
Translate Bio price target raised to $45 from $28 at Roth Capital
05/25/21 JPMorgan
Olema selloff brings 'compelling' entry point, says JPMorgan
04/30/21 Deutsche Bank
Sanofi price target raised to EUR 75 from EUR 70 at Deutsche Bank
04/29/21 Barclays
Sanofi price target raised to EUR 90 from EUR 85 at Barclays
SNY Sanofi
$52.06 /

+0.505 (+0.98%)

REGN Regeneron
$586.33 /

+5.33 (+0.92%)

SNY Sanofi
$52.06 /

+0.505 (+0.98%)

REGN Regeneron
$586.33 /

+5.33 (+0.92%)

SNY Sanofi
$52.06 /

+0.505 (+0.98%)

REGN Regeneron
$586.33 /

+5.33 (+0.92%)

REGN Regeneron
$586.33 /

+5.33 (+0.92%)

Tuesday
Hot Stocks
Sanofi says CHMP adopts positive opinion for avalglucosidase alfa in Pompe » 13:30
07/27/21
07/27
13:30
07/27/21
13:30
SNY

Sanofi

$51.55 /

-0.055 (-0.11%)

The European Medicines…

The European Medicines Agency's Committee for Medicinal Products for Human Use, or CHMP, has adopted a positive opinion for avalglucosidase alfa, a long-term enzyme replacement therapy for the treatment of people with Pompe disease, Sanofi announced. "The CHMP positive opinion and recommended indication reflect the robust data from avalglucosidase alfa's clinical development program. While Sanofi is pleased with the CHMP's recognition of the clinically meaningful improvements demonstrated in the avalglucosidase alfa development program, the CHMP considered that avalglucosidase alfa does not qualify as a New Active Substance, or NAS. As a result, Sanofi will be requesting a re-examination of the CHMP opinion in relation to the NAS conclusion. The positive opinion is based on data from the Phase 3 COMET study, which found that avalglucosidase alfa showed clinically meaningful improvements in respiratory function and movement endurance measures in people with late-onset Pompe disease," the company stated. Reference Link

ShowHide Related Items >><<
SNY Sanofi
$51.55 /

-0.055 (-0.11%)

SNY Sanofi
$51.55 /

-0.055 (-0.11%)

07/26/21 Roth Capital
Translate Bio price target raised to $45 from $28 at Roth Capital
05/25/21 JPMorgan
Olema selloff brings 'compelling' entry point, says JPMorgan
04/30/21 Deutsche Bank
Sanofi price target raised to EUR 75 from EUR 70 at Deutsche Bank
04/29/21 Barclays
Sanofi price target raised to EUR 90 from EUR 85 at Barclays
SNY Sanofi
$51.55 /

-0.055 (-0.11%)

SNY Sanofi
$51.55 /

-0.055 (-0.11%)

SNY Sanofi
$51.55 /

-0.055 (-0.11%)

Monday
Recommendations
Translate Bio price target raised to $45 from $28 at Roth Capital » 07:39
07/26/21
07/26
07:39
07/26/21
07:39
TBIO

Translate Bio

$29.99 /

-0.37 (-1.22%)

, SNY

Sanofi

$51.89 /

+0.44 (+0.86%)

Roth Capital analyst Tony…

Roth Capital analyst Tony Butler raised the firm's price target on Translate Bio (TBIO) to $45 from $28 and keeps a Buy rating on the shares. The analyst believes Translate Bio is "not being adroitly rewarded" especially if considering the transition of recombinant and/or egg-based flu vaccine currently at Sanofi (SNY) to an mRNA-based business. That said, he expects Phase I data from the COVID-19 vaccine program in Q3.

ShowHide Related Items >><<
TBIO Translate Bio
$29.99 /

-0.37 (-1.22%)

SNY Sanofi
$51.89 /

+0.44 (+0.86%)

TBIO Translate Bio
$29.99 /

-0.37 (-1.22%)

03/23/21
Fly Intel: Top five analyst downgrades
03/23/21 SVB Leerink
SVB Leerink moving to sidelines on Alexion, five others on industry concerns
03/23/21 SVB Leerink
Translate Bio downgraded to Market Perform from Outperform at SVB Leerink
03/18/21 Roth Capital
Translate Bio price target lowered to $28 from $37 at Roth Capital
SNY Sanofi
$51.89 /

+0.44 (+0.86%)

05/25/21 JPMorgan
Olema selloff brings 'compelling' entry point, says JPMorgan
04/30/21 Deutsche Bank
Sanofi price target raised to EUR 75 from EUR 70 at Deutsche Bank
04/29/21 Barclays
Sanofi price target raised to EUR 90 from EUR 85 at Barclays
04/28/21 Stifel
Protalix, Sanofi updates may signal headwinds for Avrobio, Amicus, says Stifel
TBIO Translate Bio
$29.99 /

-0.37 (-1.22%)

SNY Sanofi
$51.89 /

+0.44 (+0.86%)

SNY Sanofi
$51.89 /

+0.44 (+0.86%)

TBIO Translate Bio
$29.99 /

-0.37 (-1.22%)

SNY Sanofi
$51.89 /

+0.44 (+0.86%)

Over a week ago
Hot Stocks
Sanofi granted orphan status for polyneuropathy treatment » 11:57
07/23/21
07/23
11:57
07/23/21
11:57
SNY

Sanofi

$51.82 /

+0.37 (+0.72%)

The FDA granted Sanofi…

The FDA granted Sanofi orphan status for its monoclonal antibody for its treatment of chronic inflammatory demyelinating polyneuropathy.

ShowHide Related Items >><<
SNY Sanofi
$51.82 /

+0.37 (+0.72%)

SNY Sanofi
$51.82 /

+0.37 (+0.72%)

05/25/21 JPMorgan
Olema selloff brings 'compelling' entry point, says JPMorgan
04/30/21 Deutsche Bank
Sanofi price target raised to EUR 75 from EUR 70 at Deutsche Bank
04/29/21 Barclays
Sanofi price target raised to EUR 90 from EUR 85 at Barclays
04/28/21 Stifel
Protalix, Sanofi updates may signal headwinds for Avrobio, Amicus, says Stifel
SNY Sanofi
$51.82 /

+0.37 (+0.72%)

SNY Sanofi
$51.82 /

+0.37 (+0.72%)

SNY Sanofi
$51.82 /

+0.37 (+0.72%)

Hot Stocks
GeoVax Labs announces presentation on Sudan Ebolavirus vaccine data » 09:10
07/22/21
07/22
09:10
07/22/21
09:10
GOVX

GeoVax Labs

$4.36 /

+0.075 (+1.75%)

GeoVax Labs announced the…

GeoVax Labs announced the presentation of data from a study of its preventive vaccine against Sudan Ebolavirus. The presentation was titled "A single immunization of guinea pigs with a modified vaccinia Ankara virus producing Sudan virus-like particles protects from Sudan virus lethal challenge." In her talk, Dr. Malherbe discussed the preclinical efficacy studies of GeoVax's vaccine, a novel vaccine candidate for SUDV constructed on an MVA vector expressing two immunogens derived from the Sudan virus. Upon vaccination, these immunogens form Virus Like Particles in the host, which in turn induce immunity against subsequent infections with SUDV. Immunogenicity and efficacy of MVA-SUDV-VLP were tested in a guinea pig lethal challenge model, in which a single intramuscular dose of the GeoVax vaccine protected 100% of animals challenged with a lethal dose of SUDV. A comparison between prime and prime-boost vaccinations of guinea pigs with MVA-SUDV-VLP showed that both regimens elicited SUDV-specific binding and neutralizing antibody responses, and that the second immunization enhanced these responses. Challenge of vaccinated animals with guinea pig-adapted SUDV demonstrated a complete protection against death and disease by the prime and the prime-boost regimens. Importantly, there was no difference in outcomes between the prime and the prime-boost vaccine regimens thus demonstrating the efficacy of a single dose of MVA-SUDV-VLP. This is the first report that a replication-deficient MVA vector may confer full protection against SUDV after a single dose.

ShowHide Related Items >><<
GOVX GeoVax Labs
$4.36 /

+0.075 (+1.75%)

GOVX GeoVax Labs
$4.36 /

+0.075 (+1.75%)

11/19/20 Maxim
GeoVax Labs initiated with a Buy at Maxim
11/19/20 Maxim
GeoVax Labs initiated with a Buy at Maxim
  • 25
    Sep
Conference/Events
Piper Sandler biotech analysts hold an analyst/industry conference call » 09:51
07/15/21
07/15
09:51
07/15/21
09:51
RGNX

Regenxbio

$35.60 /

-0.36 (-1.00%)

, ROG

Rogers Corporation

$193.11 /

-1.44 (-0.74%)

, ADVM

Adverum Biotechnologies

$3.08 /

-0.075 (-2.38%)

, SNY

Sanofi

$51.63 /

-0.74 (-1.41%)

, JNJ

Johnson & Johnson

$169.40 /

-0.8 (-0.47%)

, BIIB

Biogen

$338.50 /

-13.56 (-3.85%)

, AGTC

Applied Genetic

$3.56 /

-0.02 (-0.56%)

, ISEE

Iveric bio

$9.34 /

-0.08 (-0.85%)

, GSGTF

Gensight Biologics

$9.90 /

+ (+0.00%)

Biotechnology Analysts…

Biotechnology Analysts Rahimi & Raymond, along with Roger A. Goldberg, MD, MBA, Ophthalmologist at Bay Area Retina Associates discuss gene therapy for ocular disease on an Analyst/Industry conference call to be held on July 15 at 10 am. Webcast Link

ShowHide Related Items >><<
SNY Sanofi
$51.63 /

-0.74 (-1.41%)

ROG Rogers Corporation
$193.11 /

-1.44 (-0.74%)

RGNX Regenxbio
$35.60 /

-0.36 (-1.00%)

JNJ Johnson & Johnson
$169.40 /

-0.8 (-0.47%)

ISEE Iveric bio
$9.34 /

-0.08 (-0.85%)

BIIB Biogen
$338.50 /

-13.56 (-3.85%)

AGTC Applied Genetic
$3.56 /

-0.02 (-0.56%)

ADVM Adverum Biotechnologies
$3.08 /

-0.075 (-2.38%)

RGNX Regenxbio
$35.60 /

-0.36 (-1.00%)

07/09/21 Chardan
Regenxbio coverage transferred at Chardan
04/29/21 Chardan
Chardan downgrades Adverum after serious adverse reaction disclosure
04/05/21 Morgan Stanley
Regenxbio AAV9 patent challenged by Passage Bio, says Morgan Stanley
02/09/21 Morgan Stanley
Sarepta denied motion to dismiss 'Wilson Wolf' case, says Morgan Stanley
ROG Rogers Corporation
$193.11 /

-1.44 (-0.74%)

06/09/21 Wolfe Research
Rogers Corporation initiated with an Outperform at Wolfe Research
05/26/21
Fly Intel: Top five analyst initiations
05/26/21 Canaccord
Canaccord starts Rogers with Buy on electrification benefits
05/26/21 Canaccord
Rogers Corporation initiated with a Buy at Canaccord
ADVM Adverum Biotechnologies
$3.08 /

-0.075 (-2.38%)

07/09/21 Chardan
Adverum Biotechnologies coverage transferred at Chardan
05/03/21 SVB Leerink
Adverum Biotechnologies downgraded to Market Perform at SVB Leerink
05/03/21 SVB Leerink
Adverum Biotechnologies downgraded to Market Perform from Outperform at SVB Leerink
SNY Sanofi
$51.63 /

-0.74 (-1.41%)

05/25/21 JPMorgan
Olema selloff brings 'compelling' entry point, says JPMorgan
04/30/21 Deutsche Bank
Sanofi price target raised to EUR 75 from EUR 70 at Deutsche Bank
04/29/21 Barclays
Sanofi price target raised to EUR 90 from EUR 85 at Barclays
04/28/21 Stifel
Protalix, Sanofi updates may signal headwinds for Avrobio, Amicus, says Stifel
JNJ Johnson & Johnson
$169.40 /

-0.8 (-0.47%)

07/08/21 Stifel
Vor Biopharma, Janssen collaboration benefits both parties, says Stifel
07/02/21 Cantor Fitzgerald
J&J vaccine shows 'strong' activist against Delta, says Cantor Fitzgerald
06/28/21 Cantor Fitzgerald
J&J opioid settlement removes share overhang, says Cantor Fitzgerald
06/22/21 JPMorgan
Opioid settlement would be best case for manufacturers, says JPMorgan
BIIB Biogen
$338.50 /

-13.56 (-3.85%)

07/13/21 Oppenheimer
Prothena price target raised to $76 from $54 at Oppenheimer
07/09/21 Stifel
FDA call for probe 'noise' for Biogen, unlikely to impact Aduhelm, says Stifel
07/08/21 Deutsche Bank
Roche upgraded to Buy from Hold at Deutsche Bank
06/28/21 RBC Capital
Biogen price target lowered to $354 from $400 at RBC Capital
AGTC Applied Genetic
$3.56 /

-0.02 (-0.56%)

07/09/21 Chardan
Applied Genetic coverage transferred at Chardan
06/14/21 BTIG
Applied Genetic initiated with a Buy at BTIG
04/19/21 Roth Capital
Roth Capital 'bullish' on Applied Genetic's technology, pipeline outlook
04/13/21 Roth Capital
Roth Capital sees Applied Genetic's XLRS licensing as vote of confidence
ISEE Iveric bio
$9.34 /

-0.08 (-0.85%)

07/06/21 Credit Suisse
Iveric bio price target raised to $16 from $14 at Credit Suisse
08/13/20 Credit Suisse
Iveric bio initiated with an Outperform at Credit Suisse
GSGTF Gensight Biologics
$9.90 /

+ (+0.00%)

07/09/21 Chardan
Gensight Biologics coverage transferred at Chardan
02/19/21 Chardan
Chardan doubles Gensight target, makes top pick for 2021
09/15/20 Chardan
Gensight Biologics price target raised to EUR 10 from EUR 8.50 at Chardan
SNY Sanofi
$51.63 /

-0.74 (-1.41%)

ROG Rogers Corporation
$193.11 /

-1.44 (-0.74%)

RGNX Regenxbio
$35.60 /

-0.36 (-1.00%)

JNJ Johnson & Johnson
$169.40 /

-0.8 (-0.47%)

ISEE Iveric bio
$9.34 /

-0.08 (-0.85%)

BIIB Biogen
$338.50 /

-13.56 (-3.85%)

AGTC Applied Genetic
$3.56 /

-0.02 (-0.56%)

ADVM Adverum Biotechnologies
$3.08 /

-0.075 (-2.38%)

  • 13
    Jul
  • 28
    Jan
  • 08
    Jan
  • 13
    Aug
SNY Sanofi
$51.63 /

-0.74 (-1.41%)

JNJ Johnson & Johnson
$169.40 /

-0.8 (-0.47%)

BIIB Biogen
$338.50 /

-13.56 (-3.85%)

SNY Sanofi
$51.63 /

-0.74 (-1.41%)

JNJ Johnson & Johnson
$169.40 /

-0.8 (-0.47%)

ISEE Iveric bio
$9.34 /

-0.08 (-0.85%)

BIIB Biogen
$338.50 /

-13.56 (-3.85%)

AGTC Applied Genetic
$3.56 /

-0.02 (-0.56%)

ADVM Adverum Biotechnologies
$3.08 /

-0.075 (-2.38%)

JNJ Johnson & Johnson
$169.40 /

-0.8 (-0.47%)

BIIB Biogen
$338.50 /

-13.56 (-3.85%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.